Literature DB >> 33307492

Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools.

Lorenzo Gerratana1, Andrew A Davis2, Maurizio Polano3, Qiang Zhang4, Ami N Shah4, Chenyu Lin4, Debora Basile5, Giuseppe Toffoli3, Firas Wehbe6, Fabio Puglisi5, Amir Behdad7, Leonidas C Platanias4, William J Gradishar4, Massimo Cristofanilli8.   

Abstract

BACKGROUND: Liquid biopsy provides real-time data about prognosis and actionable mutations in metastatic breast cancer (MBC). The aim of this study was to explore the combination of circulating tumour DNA (ctDNA) analysis and circulating tumour cells (CTCs) enumeration in estimating target organs more susceptible to MBC involvement.
METHODS: This retrospective study analysed 88 MBC patients characterised for both CTCs and ctDNA at baseline. CTCs were isolated through the CellSearch kit, while ctDNA was analysed using the Guardant360 NGS-based assay. Sites of disease were collected on the basis of imaging. Associations were explored both through uni- and multivariate logistic regression and Fisher's exact test and the random forest machine learning algorithm.
RESULTS: After multivariate logistic regression, ESR1 mutation was the only significant factor associated with liver metastases (OR 8.10), while PIK3CA was associated with lung localisations (OR 3.74). CTC enumeration was independently associated with bone metastases (OR 10.41) and TP53 was associated with lymph node localisations (OR 2.98). The metastatic behaviour was further investigated through a random forest machine learning algorithm. Bone involvement was described by CTC enumeration and alterations in ESR1, GATA3, KIT, CDK4 and ERBB2, while subtype, CTC enumeration, inflammatory BC diagnosis, ESR1 and KIT aberrations described liver metastases. PIK3CA, MET, AR, CTC enumeration and TP53 were associated with lung organotropism. The model, moreover, showed that AR, CCNE1, ESR1, MYC and CTC enumeration were the main drivers in HR positive MBC metastatic pattern.
CONCLUSIONS: These results indicate that ctDNA and CTCs enumeration could provide useful insights regarding MBC organotropism, suggesting a possible role for future monitoring strategies that dynamically focus on high-risk organs defined by tumourbiology.
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Circulating tumour DNA; Circulating tumour cell; Liquid biopsy; Metastatic breast cancer; Organotropism; Precision medicine

Mesh:

Substances:

Year:  2020        PMID: 33307492     DOI: 10.1016/j.ejca.2020.11.005

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis.

Authors:  Zheqi Li; Yang Wu; Megan E Yates; Nilgun Tasdemir; Amir Bahreini; Jian Chen; Kevin M Levine; Nolan M Priedigkeit; Azadeh Nasrazadani; Simak Ali; Laki Buluwela; Spencer Arnesen; Jason Gertz; Jennifer K Richer; Benjamin Troness; Dorraya El-Ashry; Qiang Zhang; Lorenzo Gerratana; Youbin Zhang; Massimo Cristofanilli; Maritza A Montanez; Prithu Sundd; Callen T Wallace; Simon C Watkins; Caterina Fumagalli; Elena Guerini-Rocco; Li Zhu; George C Tseng; Nikhil Wagle; Jason S Carroll; Paul Jank; Carsten Denkert; Maria M Karsten; Jens-Uwe Blohmer; Ben H Park; Peter C Lucas; Jennifer M Atkinson; Adrian V Lee; Steffi Oesterreich
Journal:  Cancer Res       Date:  2022-04-01       Impact factor: 12.701

2.  Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.

Authors:  Bastien Nguyen; Christopher Fong; Anisha Luthra; Shaleigh A Smith; Renzo G DiNatale; Subhiksha Nandakumar; Henry Walch; Walid K Chatila; Ramyasree Madupuri; Ritika Kundra; Craig M Bielski; Brooke Mastrogiacomo; Mark T A Donoghue; Adrienne Boire; Sarat Chandarlapaty; Karuna Ganesh; James J Harding; Christine A Iacobuzio-Donahue; Pedram Razavi; Ed Reznik; Charles M Rudin; Dmitriy Zamarin; Wassim Abida; Ghassan K Abou-Alfa; Carol Aghajanian; Andrea Cercek; Ping Chi; Darren Feldman; Alan L Ho; Gopakumar Iyer; Yelena Y Janjigian; Michael Morris; Robert J Motzer; Eileen M O'Reilly; Michael A Postow; Nitya P Raj; Gregory J Riely; Mark E Robson; Jonathan E Rosenberg; Anton Safonov; Alexander N Shoushtari; William Tap; Min Yuen Teo; Anna M Varghese; Martin Voss; Rona Yaeger; Marjorie G Zauderer; Nadeem Abu-Rustum; Julio Garcia-Aguilar; Bernard Bochner; Abraham Hakimi; William R Jarnagin; David R Jones; Daniela Molena; Luc Morris; Eric Rios-Doria; Paul Russo; Samuel Singer; Vivian E Strong; Debyani Chakravarty; Lora H Ellenson; Anuradha Gopalan; Jorge S Reis-Filho; Britta Weigelt; Marc Ladanyi; Mithat Gonen; Sohrab P Shah; Joan Massague; Jianjiong Gao; Ahmet Zehir; Michael F Berger; David B Solit; Samuel F Bakhoum; Francisco Sanchez-Vega; Nikolaus Schultz
Journal:  Cell       Date:  2022-02-03       Impact factor: 66.850

Review 3.  Detection of circulating tumor cells: opportunities and challenges.

Authors:  Siwei Ju; Cong Chen; Jiahang Zhang; Lin Xu; Xun Zhang; Zhaoqing Li; Yongxia Chen; Jichun Zhou; Feiyang Ji; Linbo Wang
Journal:  Biomark Res       Date:  2022-08-13

Review 4.  Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer.

Authors:  Ana Julia Aguiar de Freitas; Rhafaela Lima Causin; Muriele Bertagna Varuzza; Stéphanie Calfa; Cassio Murilo Trovo Hidalgo Filho; Tatiana Takahasi Komoto; Cristiano de Pádua Souza; Márcia Maria Chiquitelli Marques
Journal:  Int J Mol Sci       Date:  2022-09-01       Impact factor: 6.208

5.  Verification of a Novel Minimally Invasive Device for the Isolation of Rare Circulating Tumor Cells (CTC) in Cancer Patients' Blood.

Authors:  Paul Friedrich Geus; Felix Hehnen; Sophia Krakowski; Klaus Lücke; Dave S B Hoon; Nikolaj Frost; Ulrich Kertzscher; Gabi Wendt
Journal:  Cancers (Basel)       Date:  2022-09-29       Impact factor: 6.575

6.  Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics.

Authors:  Weikai Xiao; Guochun Zhang; Bo Chen; Xiaoqing Chen; Lingzhu Wen; Jianguo Lai; Xuerui Li; Min Li; Hao Liu; Jing Liu; Han Han-Zhang; Analyn Lizaso; Ning Liao
Journal:  J Cancer       Date:  2021-05-27       Impact factor: 4.207

7.  Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer.

Authors:  Lorenzo Gerratana; Andrew A Davis; Qiang Zhang; Debora Basile; Giovanna Rossi; Kimberly Strickland; Alessandra Franzoni; Lorenzo Allegri; Zhaomei Mu; Youbin Zhang; Lisa E Flaum; Giuseppe Damante; William John Gradishar; Leonidas C Platanias; Amir Behdad; Hushan Yang; Fabio Puglisi; Massimo Cristofanilli
Journal:  JCO Precis Oncol       Date:  2021-06-08

8.  Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC.

Authors:  Charlotte Rypens; François Bertucci; Pascal Finetti; Fredika Robertson; Sandra V Fernandez; Naoto Ueno; Wendy A Woodward; Kenneth Van Golen; Peter Vermeulen; Luc Dirix; Patrice Viens; Daniel Birnbaum; Gayathri R Devi; Massimo Cristofanilli; Steven Van Laere
Journal:  NPJ Breast Cancer       Date:  2022-01-18

Review 9.  Role of ctDNA in Breast Cancer.

Authors:  Marta Sant; Adrià Bernat-Peguera; Eudald Felip; Mireia Margelí
Journal:  Cancers (Basel)       Date:  2022-01-09       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.